



# National Newborn Screening Status Report

Updated 04/22/11

The U.S. National Screening Status Report lists the status of newborn screening in the United States.

Dot "●" indicates that screening for the condition is universally required by Law or Rule and fully implemented

**A** = universally offered but not yet required, **B** = offered to select populations, or by request, **C** = testing required but not yet implemented

**D** = likely to be detected (and reported) as a by-product of MRM screening (MS/MS) targeted by Law or Rule

STATE	Core <sup>1</sup> Conditions										Additional Conditions Included in Screening Panel (universally required unless otherwise indicated)	
	Hearing	Endocrine		Hemoglobin			Other					
	HEAR	CH	CAH	Hb S/S	Hb S/A	Hb S/C	BIO	GALT	CF	SCID		
Alabama	●	●	●	●	●	●	●	●	●	●		
Alaska	●	●	●	●	●	●	●	●	●	●		
Arizona	A	●	●	●	●	●	●	●	●	●		
Arkansas	●	●	●	●	●	●	●	●	●	●		
California	B	●	●	●	●	●	●	●	●	●	A	HHH; PRO; EMA ; OTC, MTHFR (D)
Colorado	●	●	●	●	●	●	●	●	●	●		
Connecticut	●	●	●	●	●	●	●	●	●	●		HHH; HIV <sup>2</sup> ; NKH
D.C.	●	●	●	●	●	●	●	●	●	●		G6PD
Delaware	●	●	●	●	●	●	●	●	●	●		
Florida	●	●	●	●	●	●	●	●	●	●		
Georgia	A	●	●	●	●	●	●	●	●	●		
Hawaii	●	●	●	●	●	●	●	●	●	●		
Idaho	A	●	●	●	●	●	●	●	●	●		
Illinois	●	●	●	●	●	●	●	●	●	●		Pompe, Gaucher, Fabry (B) CPS (D), NKH, 5-OXO, HIV <sup>2</sup>
Indiana	●	●	●	●	●	●	●	●	●	●		
Iowa	●	●	●	●	●	●	●	●	●	●		
Kansas	●	●	●	●	●	●	●	●	●	●		
Kentucky	B	●	●	●	●	●	●	●	●	●		
Louisiana	●	●	●	●	●	●	●	●	●	●	A	
Maine	A	●	●	●	●	●	●	●	●	●		HHH; CPS (D)
Maryland	●	●	●	●	●	●	●	●	●	●		EMA
Massachusetts	●	●	●	●	●	●	●	●	●	●	A	TOXO; HHH, CPS (D)
Michigan	●	●	●	●	●	●	●	●	●	●	C	
Minnesota	●	●	●	●	●	●	●	●	●	●		
Mississippi	●	●	●	●	●	●	●	●	●	●		5-OXO; CPS; HHH
Missouri	●	●	●	●	●	●	●	●	●	●		
Montana	●	●	●	●	●	●	●	●	●	●		
Nebraska	A	●	●	●	●	●	●	●	●	●		5-OXO; HHH; NKH (A)
Nevada	A	●	●	●	●	●	●	●	●	●		
New Hampshire	A	●	●	●	●	●	●	●	●	●		TOXO
New Jersey	●	●	●	●	●	●	●	●	●	●		
New Mexico	●	●	●	●	●	●	●	●	●	●		
New York	●	●	●	●	●	●	●	●	●	●	●	HIV; HHH; Krabbe Disease
North Carolina	●	●	●	●	●	●	●	●	●	●		
North Dakota	A	●	●	●	●	●	●	●	●	●		HHH; NKH
Ohio	●	●	●	●	●	●	●	●	●	●		
Oklahoma	●	●	●	●	●	●	C	●	●	●		
Oregon	A	●	●	●	●	●	●	●	●	●		
Pennsylvania	●	●	●	●	●	●	●	●	●	●		5-OXO; CPS; G6PD; HHH; NKH (B)
Rhode Island	●	●	●	●	●	●	●	●	●	●		
South Carolina	●	●	●	●	●	●	●	●	●	●		
South Dakota	A	●	●	●	●	●	●	●	●	●		5-OXO; EMA; HHH; NKH
Tennessee	●	●	●	●	●	●	●	●	●	●		HHH; NKH
Texas	B	●	●	●	●	●	●	●	●	●	B	
Utah	●	●	●	●	●	●	●	●	●	●		
Vermont	●	●	●	●	●	●	●	●	●	●		
Virginia	●	●	●	●	●	●	●	●	●	●		
Washington	A	●	●	●	●	●	●	●	●	●		
West Virginia	●	●	●	●	●	●	●	●	●	●		
Wisconsin	●	●	●	●	●	●	●	●	●	●	●	
Wyoming	●	●	●	●	●	●	●	●	●	●		

<sup>1</sup>Terminology consistent with ACMG report - Newborn Screening: Towards a Uniform Screening Panel and System. Genet Med. 2006; 8(5) Suppl: S12-S252

<sup>2</sup>Newborn screened for HIV only if mother was not screened during pregnancy

### Additional Conditions/Abbreviations and Names

<b>BIO</b>	Biotinidase	<b>CF</b>	Cystic fibrosis	<b>GALT</b>	Transferase deficient galactosemia (Classical)	<b>HB S/C</b>	Sickle – C disease	<b>HEAR</b>	Hearing screening
<b>CAH</b>	Congenital adrenal hyperplasia	<b>CH</b>	Congenital hypothyroidism	<b>HB S/S</b>	Sickle cell anemia	<b>HB S/A</b>	S-beta thalassemia	<b>SCID</b>	Severe Combined Immunodeficiency

### Other Disorders

<b>5-OXO</b>	5-oxoprolinuria (pyroglutamic aciduria)	<b>G6PD</b>	Glucose 6 phosphate dehydrogenase	<b>NKH</b>	Nonketotic hyperglycinemia
<b>CPS</b>	Carbamoylphosphate synthetase	<b>HHH</b>	Hyperammonemia/ornithinemia/ citrullinemia (Ornithine transporter defect)	<b>PRO</b>	Prolinemia
<b>EMA</b>	Ethylmalonic encephalopathy	<b>HIV</b>	Human immunodeficiency virus	<b>TOXO</b>	Toxoplasmosis

That screening for the condition is universally required by Law or Rule and fully implemented  
**A** = universally offered but not yet required, **B** = offered to select populations, or by request, **C** = testing required but not yet implemented  
**D** = likely to be detected (and reported) as a by-product of MRM screening (MS/MS) targeted by Law or Rule

STATE	Core <sup>1</sup> Conditions - Metabolic																			
	Fatty Acid Disorders					Organic Acid Disorders								Amino Acid Disorders						
	CUD	LCHAD	MCAD	TFP	VLCAD	GA-I	HMG	IVA	3-MCC	Cbl-A,B	BKT	MUT	PROP	MCD	ASA	CIT	HCV	MSUD	PKU	TYR-I
Alabama	●	●	●	●	●	●	●	●	●	D	●	●	●	●	●	●	●	●	●	●
Alaska	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Arizona	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Arkansas	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
California	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Colorado	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Connecticut	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
D. of Columbia	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Delaware	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Florida	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Georgia	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Hawaii	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Idaho	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Illinois	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Indiana	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Iowa	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Kansas	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Kentucky	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Louisiana	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Maine	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Maryland	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Massachusetts	●	●	●	D	●	●	●	●	D	●	●	●	●	D	●	●	●	●	●	●
Michigan	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Minnesota	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Mississippi	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Missouri	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Montana	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Nebraska	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Nevada	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
New Hampshire	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
New Jersey	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
New Mexico	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
New York	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
North Carolina	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
North Dakota	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Ohio	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Oklahoma	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Oregon	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Pennsylvania	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Rhode Island	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
South Carolina	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
South Dakota	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Tennessee	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Texas	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Utah	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Vermont	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Virginia	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Washington	●	●	●	●	●	●	●	●	D	●	●	●	●	●	●	●	●	●	●	●
West Virginia	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Wisconsin	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Wyoming	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●

<sup>1</sup>Terminology consistent with ACMG report - Newborn Screening: Towards a Uniform Screening Panel and System. Genet Med. 2006; 8(5) Suppl: S12-S252

### Deficiency/Disorder Abbreviations and Names (optional nomenclature)

<b>3-MCC</b>	3-Methylcrotonyl-CoA carboxylase	<b>CUD</b>	Carnitine uptake defect (Carnitine transport defect)	<b>LCHAD</b>	Long-chain L-3- hydroxyacyl-CoA dehydrogenase	<b>PKU</b>	Phenylketonuria/hyperphenylalaninemia
<b>ASA</b>	Argininosuccinate aciduria	<b>GA-I</b>	Glutaric acidemia type 1	<b>MCAD</b>	Medium-chain acyl-CoA dehydrogenase	<b>PROP</b>	Propionic acidemia (Propionyl-CoA carboxylase)
<b>BKT</b>	Beta ketothiolase (mitochondrial acetoacetyl-CoA thiolase ; short-chain ketoacyl thiolase; T2)	<b>HCV</b>	Homocystinuria (cystathionine beta synthase)	<b>MCD</b>	Multiple carboxylase (Holocarboxylase synthetase )	<b>TFP</b>	Trifunctional protein deficiency
<b>CBL A,B</b>	Methylmalonic acidemia (Vitamin B12 Disorders)	<b>HMG</b>	3-Hydroxy 3 - methylglutaric aciduria (3-Hydroxy 3- methylglutaryl-CoA lyase )	<b>MSUD</b>	Maple syrup urine disease (branched-chain ketoacid dehydrogenase )	<b>TYR-I</b>	Tyrosinemia Type 1
<b>CIT I</b>	Citrullinemia type I (Argininosuccinate synthetase)	<b>IVA</b>	Isovaleric acidemia (Isovaleryl-CoA dehydrogenase )	<b>MUT</b>	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	<b>VLCAD</b>	Very long-chain acyl-CoA dehydrogenase

indicates that screening for the condition is universally required by Law or Rule and fully implemented  
**A** = universally offered but not yet required, **B** = offered to select populations, or by request, **C** = testing required but not yet implemented  
**D** = likely to be detected (and reported) as a by-product of MRM screening (MS/MS) targeted by Law or Rule

STATE	Secondary Target <sup>1</sup> Conditions																								
	Fatty Acid Disorders							Organic Acid Disorders						Amino Acid Disorders							Other Metabolic		Hgb		
	CACT	CPT-Ia	CPT-II	DE-RED.	GA-II	MCKAT	M/SCHAD	SC AD	2M3HBA	2MBG	3MGA	Cbl-C,D	IBG	MAL	ARG	BIOPT-BS	BIOPT-RG	CIT-II	H-PHE	MET	TYR-II	TYR-III	GALE	GALK	Variant Hgb's
Alabama	●		●		●			●	●	●	●				●	●	●	●	●	●	●			●	
Alaska	●	●	●		●		●	●	●	●	●	●	●	●	●	B	B	●	●	●	●	D	B	B	●
Arizona	D	D	D		D			D		D	D							D	D		D	D			D
Arkansas																									●
California	●	●	●		●		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●				●
Colorado	●	●	●		●		●			●	●			●				●	●	●	●				●
Connecticut	●	●	●	●	●		●				●			●				●	●	●	●	●	●	●	●
D. of Columbia	●	●	●	●	●	●	●	●	●	●	●	●	●	●	A	A	●	●	●	●	●	●	●	●	●
Delaware	●	●	●		●	D		D	●	D	●	●		●	D	D	●	●	●	●	●	●	●	●	●
Florida	●	●	●		●		●											●	●	●	●				●
Georgia	D	D	D		D	D	D	D	D	D	D	D	D	A			D	D	D	D	D	D	B	B	●
Hawaii	●	●	●		●			●	●	●	●	●	●	●	●	B	B	●	●	●	●		B	B	●
Idaho	●	●	●		●		●	●	●	●	●	●	●	●	●	B	B	●	●	●	●		B	B	●
Illinois	●	D	●	D	●	D	●	D	●	●	●	●	●	●	D	D	D	●	●	●	●				●
Indiana	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●				●
Iowa	●	●	●		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●				●
Kansas																									●
Kentucky	A	A	A		A		●	A	A	A	A	A	A	A	D	D	A	●	A	A	A				●
Louisiana																			●						●
Maine	D	D	●		●		●		D	D	●	D		●				●	D	●	D	●	●	●	●
Maryland	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	B	B	●	●	●	●	●	●	●	●
Massachusetts	D	D	A	A	D	D	A	D	D	D	●	D	A	●	D	D	A	D	D	D	D	D	D	D	●
Michigan	●	●	●	●	●	●	●	●	●	●	●	●	D	●	●	●	●	●	●	●	A	A			●
Minnesota	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Mississippi	●	●	●	A	●	A	●	●	●	●	●	●	●	●	A	A	●	●	●	●	●	A	●	●	●
Missouri	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●				●
Montana	D		D	D	D	D	D	D	D	D	D	D			D	D	D	●	D	D	D			●	
Nebraska	D	D	D	D	D	D	D	D	D	D	D	D	D	D	D	D	D	●	D	D	D	●	●	●	●
Nevada	●	●	●		●		●	●	●	●	●	●	●	●	●	B	B	●	●	●	●		B	B	A
New Hampshire	D	D			●				D	D	D				D	D	D	●	D						●
New Jersey	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
New Mexico	A	D	A		A		A	D	D	A	A	D	D	D	B	B	A	A	A	A	D	B	B	●	●
New York	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
North Carolina	●	●	●		●		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
North Dakota	●	●	●		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Ohio	●	●	●		●		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Oklahoma	●	●	●		●	D		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Oregon	●	D	●		●		●	D	D	●	●	D	D	D	B	B	●	●	●	●	●	D	B	B	●
Pennsylvania	B	B	B	B	B		B	B	B	B	B	B	B	B	B	B	B	●	B	B	B	●	●	●	●
Rhode Island		D																				●	●	●	●
South Carolina	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
South Dakota	●	●	●		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Tennessee	●	●	●	●	●	D		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Texas	D	D	D	C	D	C	C	D	D	D	D	C	C	C	D	D	D	●	D	D	D	●	●	●	●
Utah	●	●	●		●	D		●	●	D	●	●	D	●	●	●	●	●	●	●	●	●	●	●	●
Vermont	D	D	D		D				D	D	●			D				●	●	D	D	D	●	●	●
Virginia	D	D	D		D	D		D	D	D	D				D	D	D	●	D	D	D	D	D	●	●
Washington	D		D		D	D		D	D	D	D				D	D		D	D						●
West Virginia	D	D	D	D	D	D	D	D	D	D	D	D	D	D	D	D	D	●	D	D	D	●	●	●	●
Wisconsin	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Wyoming	A	A	A	A	A	A	A	A	A	A	A	A	A	A			A	●	A	A	B				●

<sup>1</sup>Terminology consistent with ACMG report - Newborn Screening: Towards a Uniform Screening Panel and System. Genet Med. 2006; 8(5) Suppl: S12-S252

### Deficiency/Disorder Abbreviations and Names (optional nomenclature)

<b>2M3HBA</b>	2-Methyl-3-hydroxy butyric aciduria	<b>CACT</b>	Carnitine acylcarnitine translocase	<b>GA-II</b>	Glutaric acidemia Type II	<b>MAL</b>	Malonic acidemia (Malonyl-CoA decarboxylase)
<b>2MBG</b>	2-Methylbutyryl-CoA dehydrogenase	<b>CBL-C,D</b>	Methylmalonic acidemia (Cbl C,D)	<b>GALE</b>	Galactose epimerase	<b>MCKAT</b>	Medium-chain ketoacyl-CoA thiolase
<b>3MGA</b>	3-Methylglutaconic aciduria	<b>CIT-II</b>	Citrullinemia type II	<b>GALK</b>	Galactokinase	<b>MET</b>	Hypermethioninemia
<b>ARG</b>	Argininemia (Arginase deficiency)	<b>CPT-Ia</b>	Carnitine palmitoyltransferase I	<b>H-PHE</b>	Benign hyperphenylalaninemia	<b>SCAD</b>	Short-chain acyl-CoA dehydrogenase
<b>BIOPT-BS</b>	Defects of biotin cofactor biosynthesis	<b>CPT-II</b>	Carnitine palmitoyltransferase II	<b>IBG</b>	Isobutyryl-CoA dehydrogenase	<b>TYR-II</b>	Tyrosinemia type II
<b>BIOPT-REG</b>	Defects of biotin cofactor regeneration	<b>De-Red</b>	Dienoyl-CoA reductase	<b>M/SCHAD</b>	Medium/Short chain L-3-hydroxy acyl-CoA dehydrogenase	<b>TYR-III</b>	Tyrosinemia type III